Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction.
暂无分享,去创建一个
Jie Ren | Attila Kovacs | Yibin Wang | Anthony J. Muslin | Shaosong Zhang | Jie Ren | Yibin Wang | Shaosong Zhang | A. Kovács | Anthony J Muslin
[1] M. Benito,et al. P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. , 2003, Molecular biology of the cell.
[2] C. Thompson,et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.
[3] N. Robinson,et al. Molecular clocks. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[4] Anthony J. Muslin,et al. 14‐3‐3 proteins block apoptosis and differentially regulate MAPK cascades , 2000, The EMBO journal.
[5] G. Lamas,et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.
[6] Attila Kovacs,et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. , 2003, The Journal of clinical investigation.
[7] B. Swynghedauw,et al. Molecular mechanisms of myocardial remodeling. , 1999, Physiological reviews.
[8] M. Pfeffer,et al. Influence of Chronic Captopril Therapy on the Infarcted Left Ventricle of the Rat , 1985, Circulation research.
[9] D. Aswad,et al. Isoaspartate in peptides and proteins: formation, significance, and analysis. , 2000, Journal of pharmaceutical and biomedical analysis.
[10] T. Yue,et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. , 1999, Circulation.
[11] R. Zhao,et al. An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation. , 2004, Cancer cell.
[12] G. Sandusky,et al. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. , 2001, Journal of molecular and cellular cardiology.
[13] P. Doevendans,et al. Targeted Inhibition of p38 Mitogen-activated Protein Kinase Antagonizes Cardiac Injury and Cell Death Following Ischemia-Reperfusion in Vivo* , 2004, Journal of Biological Chemistry.
[14] M. Pfeffer,et al. Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.
[15] Ellen M. Langer,et al. Bcl-xL Deamidation Is a Critical Switch in the Regulation of the Response to DNA Damage , 2002, Cell.
[16] Anthony J. Muslin,et al. Role of 14-3-3-Mediated p38 Mitogen-Activated Protein Kinase Inhibition in Cardiac Myocyte Survival , 2003, Circulation research.
[17] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[18] Anthony J. Muslin,et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. , 1999, The Journal of clinical investigation.
[19] E. Murphy,et al. Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning , 2001 .
[20] M. Pfeffer,et al. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. , 1987, Circulation.
[21] J. Blenis,et al. ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.
[22] R. Patten,et al. New concepts in post-infarction ventricular remodeling. , 2003, Reviews in cardiovascular medicine.
[23] D. Geddes,et al. Critical appraisal of the mouse model of myocardial infarction , 2004, Experimental physiology.